MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-12-2022
ResMed Balance Sheet 2011-2025 | RMD
Annual Balance Sheet ResMed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
513 M | 372 M | 722 M | 1.12 B | 92.8 M | 257 M | 444 M | -417 M | -605 M | -575 M | -559 M | -635 M |
Long Term Debt |
765 M | 643 M | 1.16 B | 1.26 B | 270 M | 1.08 B | 875 M | 301 M | 301 M | 769 K | 251 M | 100 M |
Long Term Debt Current |
21.9 M | 23.6 M | 21.3 M | - | - | - | - | - | 18 K | 300 M | 52 K | 163 K |
Total Non Current Liabilities |
1.05 B | 931 M | 1.49 B | 1.48 B | 494 M | 1.15 B | 926 M | 330 M | 333 M | 26.2 M | 277 M | 129 M |
Total Current Liabilities |
689 M | 912 M | 603 M | 556 M | 511 M | 360 M | 639 M | 267 M | 270 M | 574 M | 253 M | 209 M |
Total Liabilities |
1.74 B | 1.84 B | 2.09 B | 2.04 B | 1 B | 1.51 B | 1.56 B | 597 M | 603 M | 600 M | 530 M | 338 M |
Deferred Revenue |
109 M | 110 M | 98.6 M | 88.7 M | 60.8 M | 51.9 M | 50 M | 36.1 M | 42.4 M | 45 M | 41.6 M | 45.1 M |
Retained Earnings |
3.61 B | 3.08 B | 2.83 B | 2.44 B | 2.43 B | 2.32 B | 2.16 B | 1.98 B | 1.78 B | 1.58 B | 1.37 B | 1.11 B |
Total Assets |
5.1 B | 4.73 B | 4.59 B | 4.11 B | 3.06 B | 3.47 B | 3.26 B | 2.18 B | 2.36 B | 2.21 B | 2.14 B | 2.07 B |
Cash and Cash Equivalents |
274 M | 295 M | 463 M | 147 M | 189 M | 822 M | 731 M | 717 M | 906 M | 876 M | 810 M | 735 M |
Book Value |
3.36 B | 2.89 B | 2.5 B | 2.07 B | 2.06 B | 1.96 B | 1.69 B | 1.59 B | 1.76 B | 1.61 B | 1.61 B | 1.73 B |
Total Shareholders Equity |
3.36 B | 2.89 B | 2.5 B | 2.07 B | 2.06 B | 1.96 B | 1.69 B | 1.59 B | 1.76 B | 1.61 B | 1.61 B | 1.73 B |
All numbers in USD currency
Quarterly Balance Sheet ResMed
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 669 M | 668 M | 794 M | 643 M | 643 M | 814 M | 1.04 B | 1.16 B | 1.16 B | 1.29 B | 1.21 B | 1.26 B | 1.26 B | 1.19 B | 518 M | 270 M | 270 M | - | 1.02 B | 1.08 B | 1.17 B | 869 M | 874 M | 873 M | 873 M | 401 M | 501 M | 301 M | 301 M | 450 M | 376 M | 301 M | 301 M | 436 M | 790 K | 769 K | 769 K | 301 M | 266 M | 251 M | 251 M | 225 M | 130 M | 100 M | 100 M |
Total Non Current Liabilities |
- | - | - | 959 M | 968 M | 1.08 B | 931 M | 931 M | 1.13 B | 1.35 B | 1.49 B | 1.49 B | 1.6 B | 1.49 B | 1.48 B | 1.48 B | 1.47 B | 746 M | 494 M | 494 M | 188 M | 1.09 B | 1.15 B | 1.15 B | 930 M | 929 M | 924 M | 924 M | 449 M | 537 M | 328 M | 330 M | 479 M | 402 M | 333 M | 333 M | 464 M | 31 M | 26.2 M | 26.2 M | 328 M | 293 M | 277 M | 277 M | 252 M | 161 M | 129 M | 129 M |
Total Liabilities |
- | - | - | 1.63 B | 1.59 B | 1.7 B | 1.84 B | 1.84 B | 1.71 B | 1.94 B | 2.09 B | 2.09 B | 2.1 B | 2.04 B | 2.04 B | 2.04 B | 1.9 B | 1.17 B | 1 B | 1 B | 1.54 B | 1.44 B | 1.51 B | 1.51 B | 1.61 B | 1.55 B | 1.56 B | 1.56 B | 715 M | 794 M | 594 M | 597 M | 738 M | 656 M | 603 M | 603 M | 707 M | 642 M | 600 M | 600 M | 579 M | 546 M | 530 M | 530 M | 480 M | 386 M | 338 M | 338 M |
Deferred Revenue |
- | - | - | 112 M | 112 M | 113 M | 110 M | 110 M | 105 M | 102 M | 98.6 M | 98.6 M | 93 M | 87 M | 88.7 M | 88.7 M | 72.7 M | 64.8 M | 60.8 M | 58 M | 53.3 M | 53.3 M | 51.9 M | 51.9 M | 46.4 M | 47.7 M | 50 M | 50 M | 36.1 M | 34.8 M | 36.1 M | 36.1 M | 36.9 M | 39.5 M | 42.4 M | 42.4 M | 42.6 M | 43.9 M | 45 M | 45 M | 43.8 M | 43 M | 41.6 M | 41.6 M | 41.8 M | 41.9 M | 45.1 M | 45.1 M |
Retained Earnings |
- | - | - | 3.48 B | 3.36 B | 3.22 B | 3.08 B | 3.08 B | 3.08 B | 2.95 B | 2.83 B | 2.83 B | 2.6 B | 2.5 B | 2.44 B | 2.44 B | 2.37 B | 2.3 B | 2.43 B | 2.43 B | 2.31 B | 2.35 B | 2.32 B | 2.32 B | 2.22 B | 2.19 B | 2.16 B | 2.16 B | 2.06 B | 2.01 B | 1.98 B | 1.98 B | 1.88 B | 1.82 B | 1.78 B | 1.78 B | 1.67 B | 1.62 B | 1.58 B | 1.58 B | 1.47 B | 1.41 B | 1.37 B | 1.37 B | 1.23 B | 1.16 B | 1.11 B | 1.11 B |
Total Assets |
- | - | - | 4.91 B | 4.73 B | 4.73 B | 4.73 B | 4.73 B | 4.57 B | 4.62 B | 4.59 B | 4.59 B | 4.35 B | 4.15 B | 4.11 B | 4.11 B | 3.86 B | 3.07 B | 3.06 B | 3.06 B | 3.56 B | 3.49 B | 3.47 B | 3.47 B | 3.32 B | 3.32 B | 3.26 B | 3.26 B | 2.24 B | 2.25 B | 2.18 B | 2.18 B | 2.33 B | 2.31 B | 2.36 B | 2.36 B | 2.35 B | 2.33 B | 2.21 B | 2.21 B | 2.33 B | 2.24 B | 2.14 B | 2.14 B | 2.04 B | 1.94 B | 2.07 B | 2.07 B |
Cash and Cash Equivalents |
- | - | - | 202 M | 194 M | 276 M | 295 M | 295 M | 256 M | 421 M | 463 M | 421 M | 204 M | 172 M | 204 M | 172 M | 149 M | 230 M | 149 M | 230 M | 859 M | 811 M | 859 M | 811 M | 788 M | 782 M | 788 M | 782 M | 659 M | 822 M | 659 M | 822 M | 881 M | 882 M | 881 M | 882 M | 973 M | 977 M | 973 M | 977 M | 958 M | 891 M | 958 M | 891 M | 723 M | 610 M | 723 M | 610 M |
Book Value |
- | - | - | 3.28 B | 3.15 B | 3.03 B | 2.89 B | 2.89 B | 2.86 B | 2.68 B | 2.5 B | 2.5 B | 2.26 B | 2.12 B | 2.07 B | 2.07 B | 1.96 B | 1.9 B | 2.06 B | 2.06 B | 2.02 B | 2.05 B | 1.96 B | 1.96 B | 1.71 B | 1.77 B | 1.69 B | 1.69 B | 1.52 B | 1.46 B | 1.59 B | 1.59 B | 1.59 B | 1.65 B | 1.76 B | 1.76 B | 1.64 B | 1.69 B | 1.61 B | 1.61 B | 1.75 B | 1.7 B | 1.61 B | 1.61 B | 1.56 B | 1.55 B | 1.73 B | 1.73 B |
Total Shareholders Equity |
- | - | - | 3.28 B | 3.15 B | 3.03 B | 3.15 B | 3.03 B | 2.86 B | 2.86 B | 2.86 B | 2.68 B | 2.26 B | 2.26 B | 2.26 B | 2.12 B | 1.96 B | 1.96 B | 1.96 B | 1.9 B | 2.02 B | 2.05 B | 2.02 B | 2.05 B | 1.71 B | 1.77 B | 1.69 B | 1.69 B | 1.52 B | 1.46 B | 1.59 B | 1.59 B | 1.59 B | 1.65 B | 1.76 B | 1.76 B | 1.64 B | 1.69 B | 1.61 B | 1.61 B | 1.75 B | 1.7 B | 1.61 B | 1.61 B | 1.56 B | 1.55 B | 1.73 B | 1.73 B |
All numbers in USD currency
Balance Sheet is a fundamental financial report of ResMed , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 24.56 | 0.7 % | $ 1.13 B |  USA |
 |
Baxter International
BAX
|
$ 19.52 | 1.93 % | $ 9.96 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 200.48 | -0.23 % | $ 57.7 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 4.68 | 0.21 % | $ 94.4 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.71 | -4.45 % | $ 30.1 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
$ 148.28 | -0.1 % | $ 3.62 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 170.21 | 0.82 % | $ 5.31 B | USA |
 |
Alcon
ALC
|
$ 79.15 | 0.43 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 41.07 | -3.09 % | $ 1.93 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
electroCore
ECOR
|
$ 4.85 | 2.11 % | $ 26.7 K | USA |
 |
Repro Med Systems
KRMD
|
$ 5.8 | 0.35 % | $ 264 M | USA |
 |
AngioDynamics
ANGO
|
$ 13.42 | 2.13 % | $ 548 M | USA |
 |
The Cooper Companies
COO
|
$ 81.36 | -0.88 % | $ 16.2 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.04 | -1.14 % | $ 1.86 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 111.73 | 2.6 % | $ 5.41 B | USA |
 |
Masimo Corporation
MASI
|
$ 137.35 | -0.72 % | $ 7.32 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 80.24 | -3.89 % | $ 4.04 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.22 | -0.27 % | $ 190 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 86.49 | -0.24 % | $ 5.04 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 559.7 | 3.2 % | $ 199 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.49 | - | $ 185 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.23 | -7.65 % | $ 22.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.36 | -7.4 % | $ 28.7 M | USA |
 |
Nephros
NEPH
|
$ 4.98 | -0.8 % | $ 51.7 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.07 | 0.46 % | $ 3.8 B | USA |
 |
Pro-Dex
PDEX
|
$ 44.0 | 1.43 % | $ 145 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 23.49 | -2.65 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
$ 253.98 | 0.82 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
$ 2.35 | -1.05 % | $ 190 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.04 | -1.4 % | $ 674 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
$ 160.09 | 1.72 % | $ 8.92 M | USA |
 |
Utah Medical Products
UTMD
|
$ 57.54 | -0.96 % | $ 209 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.43 | -1.21 % | $ 2.32 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.84 | 1.99 % | $ 25.1 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 126.88 | 0.17 % | $ 5.94 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 271.82 | 1.6 % | $ 19.8 B | USA |